Drug Trial Radar · NCT06579092
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
310
Actual
Start
Oct 8, 2024
Primary completion
Nov 21, 2025
Study completion Nov 21, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity
Conditions
- Obesity or Overweight
Interventions
AZD5004Drug
AZD5004 film-coated tablet once daily during 36 weeks
PlaceboDrug
Placebo matching AZD5004 film-coated tablet once daily during 36 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight from baselineTime frame: 26 weeks
- Achieved Weight Loss ≥ 5% From BaselineTime frame: 26 weeks
Locations
62 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Chandler, Arizona
Research Site
Huntington Park, California
Research Site
La Mesa, California
Research Site
Lincoln, California
Research Site
Walnut Creek, California
Research Site
Hialeah, Florida
Research Site
Orlando, Florida
Research Site
Lombard, Illinois
Research Site
Valparaiso, Indiana
Research Site
West Des Moines, Iowa
Research Site
Roslindale, Massachusetts
Research Site
Farmington Hills, Michigan
Research Site
Chesterfield, Missouri
Research Site
Omaha, Nebraska
Research Site
Vestal, New York
Research Site
Durham, North Carolina
Research Site
Wilmington, North Carolina
Research Site
Fargo, North Dakota
Research Site
Beachwood, Ohio
Research Site
Cincinnati, Ohio
Research Site
North Charleston, South Carolina
Research Site
Spartanburg, South Carolina
Research Site
Knoxville, Tennessee
Research Site
Austin, Texas
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Woodway, Texas
Research Site
Ogden, Utah
Research Site
Charlottesville, Virginia
Research Site
Manassas, Virginia
Research Site
Heidelberg, Australia
Research Site
Merewether, Australia
Research Site
St Albans, Australia
Research Site
St Leonards, Australia
Research Site
Calgary, Alberta, Canada
Research Site
Surrey, British Columbia, Canada
Research Site
Victoria, British Columbia, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Guelph, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.